ArticleFrontiers in cardiovascular medicine2026
A study on the relationship between mMRC dyspnea scale and both risk stratification and poor prognosis in patients with acute pulmonary embolism.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to investigate the value of the modified Medical Research Council (mMRC) dyspnea scale in risk stratification and outcome assessment for patients with acute pulmonary embolism (APE). Methods: A retrospective analysis was performed using medical records from a tertiary care center between 2011 and 2023. The study included patients aged 18-80 years who were diagnosed with APE. Participants were categorized into groups based on pulmonary embolism risk stratification, mMRC dyspnea scale, and the presence or absence of adverse outcomes within 1 year, which included in-hospital mortality, all-cause mortality after discharge, and hospital readmission. The associations between the mMRC dyspnea scale and both APE risk stratification and 1-year adverse outcomes were evaluated. The predictive performance of the mMRC dyspnea scale for 1-year adverse prognosis was assessed using receiver operating characteristic (ROC) curve analysis to determine the optimal cut-off threshold. Results: The study demonstrated that the mMRC dyspnea scale was significantly positively correlated with risk stratification of APE ( Conclusion: The mMRC dyspnea scale demonstrates a significant association with risk stratification in patients with APE. An mMRC dyspnea grade of ≥3 is indicative of a higher risk for adverse outcomes within 1 year and may serve as a valuable prognostic indicator for predicting clinical outcomes in APE patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.